Pricing & Reimbursement - Seven Major Markets Update

Introduction
Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.

Scope
- Overview of P&R issues in the market today and their impact on branded Pharma
- Introduction to the current P&R tools utilized across the seven major markets to contain costs
- Analysis of each of the seven major markets, examining both the healthcare systems and the key P&R infrastructure
- Identification of trends and recommendations shaping national P&R environments

Report Highlights
It is now a perquisite to perform pharmacoeconomic assessments early on in the drug development process and provide cost effective evaluations to ensure access to reimbursement lists

In the, US pharma companies can expect the Federal government and insurance providers to seek out negotiations to cut drug costs. Presently, Medicare is unable to negotiate drug prices with Pharma, although a Democratic government will want to amend legislation giving it more power to challenge Pharma on drug prices

Parallel trade will continue to play a role in driving down drug prices in Europe. However, as drug price differences between EU countries decreases due to reference pricing, coupled with the claw-back system imposed on pharmacies, the incentive to use parallel traded products will progressively weaken

Reasons to Purchase
- Gain a clear understanding of the recent changes in the P&R environment across the seven major markets and how this is impacting pharma companies
- Review recent P&R trends in the seven major markets based on Datamonitor analysis and primary research conducted with key stakeholders in the industry
- Provides analysis of today's market situation, focusing on the up coming US presidential elections and the potential impact on future P&R initiatives